WASHINGTON, April 25, 2025 (GLOBE NEWSWIRE) -- Retail investors who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) in the company’s September 2024 initial public offering may have the chance to lead a securities class action lawsuit now pending in federal court. Cohen Milstein Sellers & Toll PLLC encourages individual investors with meaningful losses to consider applying to the court to serve as lead plaintiff by the upcoming June 16, 2025 deadline. [Click here for information about joining the cl ...